Oncotarget

Exploring the toxic sunscreen chemical oxybenzone, known for promoting breast cancer and its estrogenic properties. Study reveals diet-dependent effects on mammary tumorigenesis in mouse models, emphasizing the role of saturated animal fat. Understanding the complex relationship between environmental toxins and breast cancer development.

Dr. Michael H. Roehrl from Memorial Sloan Kettering Cancer Center discusses the importance of P4HA1 protein as a prognostic marker in early-stage colorectal cancer. Proteomics technology is highlighted for discovering new biomarkers, guiding personalized treatment decisions, and improving patient outcomes.

Dr. Susan E. Erdman from MIT discusses using cholera toxin to combat age-associated obesity by stimulating immune responses. The podcast explores how gut microbiota affects obesity and chronic diseases. They delve into the properties of cholera toxin and its potential as an obesity solution, highlighting the benefits of early exposure to cholera vaccine for immune system health.

Researchers conducted a retrospective study of 20,000 lung cancer patients to analyze ALK gene rearrangement prevalence, offering insights into potential drug therapies. The study highlighted higher rates of ALK rearrangement in non-smokers and Asians, emphasizing the impact of patient demographics on the presence of the gene rearrangement.

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 23. https://www.oncotarget.com/archive/v12/i23/ Research Paper (Cover) - “Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States – retrospective real world data” https://doi.org/10.18632/oncotarget.28114 News - “Excitement for our future” https://doi.org/10.18632/oncotarget.28116 (PDF Download) Editorial - “Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)” https://doi.org/10.18632/oncotarget.27995 (PDF Download) Editorial - “Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer” https://doi.org/10.18632/oncotarget.27998 (PDF Download) Keywords - ALK rearrangement, non-small cell lung cancer (NSCLC), prevalence, multi-omics, molecular signatures, BRCA, HER2, triple negative breast cancer, breast cancer, hepatocellular carcinoma, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Researchers discuss the use of bacteria in tumor-targeted therapies for prostate cancer, highlighting a study on the bacteria strain CRC2631 in mouse models. The podcast explores the toxicity, tumor targeting, and genetic stability of CRC2631 compared to VNP2009, as well as its potential in reducing metastatic burden in prostate cancer through combination therapy with an immune checkpoint blockade.

Exploring the link between Benzophenone-3 and mammary tumorigenesis, the podcast delves into the effects of this endocrine disrupting chemical on breast cancer risk. Researchers highlight the diet-dependent nature of BP-3's promotion of tumor growth, pointing to the need for more studies in animal models and humans. The episode sheds light on the potential role of estrogenic chemicals in promoting breast cancer, emphasizing the importance of evaluating environmental EDCs in varying dietary contexts.

Researchers conduct a Phase 1B clinical trial to test the efficacy of combining P10's PODRIA vaccine with chemotherapy for HR-positive/HER-2 breast cancer patients. The goal is to enhance immune responses and improve long-term survival benefits. Treatment schedules play a crucial role in generating strong antibody responses for better therapeutic outcomes.

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 22. https://www.oncotarget.com/archive/v12/i22/ Research Paper (Cover) - “P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses” https://doi.org/10.18632/oncotarget.28083 Research Paper - “Dishevelled-1 DIX and PDZ domain lysine residues regulate oncogenic Wnt signaling” https://doi.org/10.18632/oncotarget.28089 Research Paper - “THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma” https://doi.org/10.18632/oncotarget.28099 Research Paper - “Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization” https://doi.org/10.18632/oncotarget.28092 Review - “Emerging approaches of wound healing in experimental models of high-grade oral mucositis induced by anticancer therapy” https://doi.org/10.18632/oncotarget.28091 Editorial - “Future directions for immunotherapy in meningioma treatment” https://doi.org/10.18632/oncotarget.27994 (PDF Download) Editorial - “Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer” https://doi.org/10.18632/oncotarget.28007 (PDF Download) Keywords - cancer vaccine, dishevelled (DVL), next-generation sequencing (NGS), oral mucositis, meningioma, immunotherapy, HER2 low, pancreatic cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

The podcast delves into how cancer cells resist epithelial mesenchymal transition (EMT) and explores the irreversibility of MET. Researchers uncover global epigenetic programs, the role of GRHL2, and mechanisms behind resistance in epithelial tumor cells. They also discuss spatial effects on cell populations and molecular mechanisms in EMT and MET transitions.